financetom
Business
financetom
/
Business
/
CyberArk Shares Slide Despite Positive Outlook, Earnings Report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CyberArk Shares Slide Despite Positive Outlook, Earnings Report
May 2, 2024 10:51 AM

CyberArk Software Ltd ( CYBR ) reported fiscal first-quarter 2024 revenue growth of 37% year-on-year to $221.55 million, beating the analyst consensus of $213.29 million. 

The information security company posted an adjusted EPS of $0.75, which beat the analyst consensus of $0.28. The stock price declined after the print.

Segments: Revenues from Subscriptions expanded 69% Y/Y to $156.2 million. Maintenance and professional services were $62.4 million vs. $65.1 million Y/Y.

Also Read: Why Microsoft, Alphabet, Amazon, Palantir, And Meta Could Rise 15% In 2024, According To Analyst

Key Performance Indicators: Annual Recurring Revenue (ARR) increased 34% Y/Y to $811 million. The subscription portion of ARR was $621 million, implying a 54% Y/Y growth. 

The Maintenance portion of ARR was $190 million compared to $202 million Y/Y. Recurring revenue grew 41% Y/Y to $205.8 million. 

CyberArk held $1.4 billion in cash and equivalents as of March 31.

Outlook: CyberArk expects a fiscal second-quarter revenue of $215.0 million to $221.0 million versus the consensus of $221.0 million.

It projected an adjusted EPS of $0.34 – $0.44 versus the consensus of $0.30.

CyberArk projected fiscal 2024 revenue of $928.0 million – $938.0 million (prior $920.0 million – $930.0 million) versus the consensus of $927.1 million. 

CyberArk expects an adjusted EPS outlook of $1.88 – $2.07 (prior $1.63 – $1.81) versus the consensus of $1.76.

ARR as of December 31, 2024, will likely range between  $975 million – $990 million (prior $968.0 million – $983.0 million), up by 26% – 28%.

Cyberark Software ( CYBR ) stock gained 95% in the last 12 months. Investors can gain exposure to the stock via First Trust NASDAQ Cybersecurity ETF ( CIBR ) and IShares Cybersecurity And Tech ETF ( IHAK ) .

Price Action: CYBR shares traded lower by 2.2% at $231.76 at last check Thursday.

Now Read: Federal Reserve Takes Cautious Stand On Inflation, Powell Signals Preference For Rate Cuts Over Hikes

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved